Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Outset Medical (OM) Non Operating Income (2019 - 2025)

Historic Non Operating Income for Outset Medical (OM) over the last 7 years, with Q4 2025 value amounting to $1.7 million.

  • Outset Medical's Non Operating Income fell 1806.17% to $1.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $7.4 million, marking a year-over-year decrease of 2410.61%. This contributed to the annual value of $7.4 million for FY2025, which is 2410.61% down from last year.
  • Per Outset Medical's latest filing, its Non Operating Income stood at $1.7 million for Q4 2025, which was down 1806.17% from $1.9 million recorded in Q3 2025.
  • In the past 5 years, Outset Medical's Non Operating Income ranged from a high of $3.1 million in Q1 2024 and a low of $99000.0 during Q3 2021
  • In the last 5 years, Outset Medical's Non Operating Income had a median value of $1.9 million in 2022 and averaged $1.6 million.
  • Within the past 5 years, the most significant YoY rise in Outset Medical's Non Operating Income was 605000.0% (2021), while the steepest drop was 7565.22% (2021).
  • Over the past 5 years, Outset Medical's Non Operating Income (Quarter) stood at $123000.0 in 2021, then surged by 1450.41% to $1.9 million in 2022, then rose by 19.66% to $2.3 million in 2023, then dropped by 10.47% to $2.0 million in 2024, then dropped by 18.06% to $1.7 million in 2025.
  • Its Non Operating Income stands at $1.7 million for Q4 2025, versus $1.9 million for Q3 2025 and $1.9 million for Q2 2025.